Company Quick10K Filing
Beigene
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$0.00 784 $98,573
10-Q 2019-11-12 Quarter: 2019-09-30
10-Q 2019-08-08 Quarter: 2019-06-30
10-Q 2019-05-09 Quarter: 2019-03-31
10-K 2019-02-28 Annual: 2018-12-31
10-Q 2018-11-08 Quarter: 2018-09-30
10-Q 2018-08-09 Quarter: 2018-06-30
10-Q 2018-05-09 Quarter: 2018-03-31
10-K 2018-02-28 Annual: 2017-12-31
10-Q 2017-11-13 Quarter: 2017-09-30
10-Q 2017-08-09 Quarter: 2017-06-30
10-Q 2017-05-10 Quarter: 2017-03-31
10-K 2017-03-22 Annual: 2016-12-31
10-Q 2016-11-10 Quarter: 2016-09-30
10-Q 2016-08-10 Quarter: 2016-06-30
10-Q 2016-05-12 Quarter: 2016-03-31
10-K 2016-03-30 Annual: 2015-12-31
8-K 2020-01-24 Other Events, Exhibits
8-K 2019-12-27 Shareholder Vote
8-K 2019-12-22 Other Events, Exhibits
8-K 2019-12-12 Regulation FD, Other Events, Exhibits
8-K 2019-12-08 Other Events, Exhibits
8-K 2019-12-06 Enter Agreement, Sale of Shares
8-K 2019-11-23 Other Events, Exhibits
8-K 2019-11-14 Other Events, Exhibits
8-K 2019-11-12 Earnings, Other Events, Exhibits
8-K 2019-11-05 Other Events, Exhibits
8-K 2019-10-31 Enter Agreement, Sale of Shares, Regulation FD, Exhibits
8-K 2019-09-30 Other Events, Exhibits
8-K 2019-09-24 Other Events, Exhibits
8-K 2019-09-12 Regulation FD
8-K 2019-08-21 Other Events, Exhibits
8-K 2019-08-08 Earnings, Regulation FD, Other Events, Exhibits
8-K 2019-06-20 Regulation FD, Other Events, Exhibits
8-K 2019-06-17 Leave Agreement, Regulation FD, Other Events, Exhibits
8-K 2019-06-05 Shareholder Vote, Other Events, Exhibits
8-K 2019-06-03 Other Events, Exhibits
8-K 2019-05-09 Earnings, Other Events, Exhibits
8-K 2019-04-09 Other Events, Exhibits
8-K 2019-04-02 Other Events, Exhibits
8-K 2019-03-06 Other Events, Exhibits
8-K 2019-02-27 Earnings, Regulation FD, Other Events, Exhibits
8-K 2019-01-23 Officers
8-K 2019-01-14 Other Events, Exhibits
8-K 2019-01-06 Regulation FD, Exhibits
8-K 2018-12-19 Leave Agreement
8-K 2018-12-15 Leave Agreement, Other Events, Exhibits
8-K 2018-12-11 Shareholder Rights, Officers, Amend Bylaw, Shareholder Vote, Exhibits
8-K 2018-12-01 Other Events, Exhibits
8-K 2018-11-27 Other Events, Exhibits
8-K 2018-11-16 Other Events, Exhibits
8-K 2018-11-07 Earnings, Other Events, Exhibits
8-K 2018-10-22 Other Events, Exhibits
8-K 2018-10-12 Other Events, Exhibits
8-K 2018-09-20 Other Events, Exhibits
8-K 2018-08-31 Other Events, Exhibits
8-K 2018-08-26 Other Events, Exhibits
8-K 2018-08-08 Earnings, Other Events, Exhibits
8-K 2018-08-07 Officers, Other Events, Exhibits
8-K 2018-08-02 Enter Agreement, Other Events, Exhibits
8-K 2018-07-29 Other Events
8-K 2018-07-27 Enter Agreement, Other Events, Exhibits
8-K 2018-07-24 Earnings, Other Events, Exhibits
8-K 2018-07-22 Enter Agreement, Other Events, Exhibits
8-K 2018-06-15 Other Events, Exhibits
8-K 2018-06-06 Officers, Shareholder Vote, Other Events, Exhibits
8-K 2018-05-17 Other Events, Exhibits
8-K 2018-05-09 Earnings, Other Events, Exhibits
8-K 2018-04-30 Officers, Other Events, Exhibits
8-K 2018-04-16 Other Events, Exhibits
8-K 2018-04-10 Other Events, Exhibits
8-K 2018-04-01 Officers, Other Events, Exhibits
8-K 2018-02-28 Earnings, Other Events, Exhibits
8-K 2018-02-09 Other Events, Exhibits
8-K 2018-02-05 Other Events, Exhibits
8-K 2018-01-31 Other Events, Exhibits
8-K 2018-01-17 Enter Agreement, Other Events, Exhibits
8-K 2018-01-16 Earnings, Other Events, Exhibits
8-K 2018-01-09 Other Events, Exhibits
8-K 2018-01-07 Regulation FD, Other Events, Exhibits
8-K 2018-01-02 Other Events, Exhibits

Beigene Financials

BGNE Metrics, Comps, Filings

Annual | Quarterly

Business

We are a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer. Our internally-developed lead drug candidates are currently in late-stage clinical trials, including 21 registration or registration-enabling trials in 14 discrete cancer indications. We have submitted three new drug applications for regulatory approval in China and are planning for new drug launches and additional submissions in China and the United States in 2019 and 2020. In addition, we are marketing three in-licensed cancer drugs in China from which we have been generating product revenue since September 2017.

We started as a research and development company in Beijing in 2010, focusing on developing best-in-class oncology drugs. Over the last nine years, we have developed into a fully-integrated global biotechnology company with operations in China, the United States, Europe and Australia, including a more than 800-person global clinical development team running over 50 ongoing or planned clinical trials as of January 24, 2019. We also have a growing commercial team that is selling our existing in-licensed drugs in China and preparing for launches of our internally-developed drug candidates in China and the United States, as well as internal manufacturing capabilities in China that are operational or under construction for the clinical and commercial supply of our small molecule and biologic drug candidates.

Our lead internally-developed drug candidates include the following:


Valuation ($BB)

Market Cap, Enterprise Value

Balance Sheet ($BB)

Assets, Stockholders' Equity

Income Statement ($BB Annual)

Revenue, Gross Profit, Net Income

Cash Flow ($BB Annual)

Operating, Investing, Financing

Comps ($MM TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Abbott (ABT) 149,087 57% 22.9 4% 68,427 36,741 30,935 17,651 2,895 7,217 164,940
Eli Lilly (LLY) 106,241 77% 11.8 20% 38,666 35,809 23,229 17,810 7,843 9,937 117,668
AbbVie (ABBV) 100,912 77% 18.0 7% 57,142 65,708 32,624 25,254 4,118 7,085 127,359
Beigene (BGNE) 98,573 88% -152.1 -31% 2,150 579 434 383 -664 -642 97,723
Bristol Myers Squibb (BMY) 73,829 53% 8.4 11% 55,163 39,012 23,857 12,640 6,226 8,365 69,858
Celgene (CELG) 67,154 96% 10.4 13% 39,183 29,132 16,354 15,736 5,271 7,702 79,730
GW Pharmaceuticals (GWPH) 64,239 88% -1,554.6 -6% 843 114 114 100 -50 -41 63,656
Allergan (AGN) 54,767 85% 80.8 -4% 123,846 38,273 15,678 13,341 -5,356 939 75,841
Zoetis (ZTS) 54,569 67% 25.9 13% 10,986 8,575 6,046 4,046 1,375 2,291 59,314
Sanofi (SNY) 52,845 0% 111,408 0 0 0 0 52,184
Vertex Pharmaceuticals (VRTX) 46,842 87% 16.9 33% 7,033 1,964 3,454 2,990 2,355 2,569 43,540
Regeneron Pharmaceuticals (REGN) 35,984 0% 15.2 16% 13,174 3,418 7,237 0 2,069 2,295 34,925
Alexion Pharmaceuticals (ALXN) 28,246 71% 15.7 9% 14,568 4,404 4,499 3,191 1,334 1,835 28,827
Biomarin Pharmaceutical (BMRN) 15,774 79% 680.7 -3% 4,393 1,432 1,533 1,213 -110 24 16,336
Elanco Animal Health (ELAN) 12,085 52% 30.6 2% 8,857 3,591 3,073 1,591 144 460 14,098
Mylan (MYL) 9,779 34% 8.3 0% 31,817 19,914 11,245 3,793 34 2,748 22,896
Teva (TEVA) 9,708 44% -13.7 -6% 59,424 44,173 17,720 7,741 -3,851 -2,437 33,498
Sarepta Therapeutics (SRPT) 9,465 0% -16.1 -33% 1,748 649 345 0 -570 -518 8,352
Ionis Pharmaceuticals (IONS) 9,097 57% 30.7 17% 2,878 1,421 799 459 495 287 8,825
Sage Therapeutics (SAGE) 8,814 51% -14.1 -47% 1,316 113 2 1 -613 -612 8,646

Balance Sheet ($MM)2016-12-312017-12-312018-12-31
Cash88140741
Accounts Receivable2941
Inventory1116
PP&E2663157
Assets4061,0462,250
Accounts Payable1270113
Long-Term Debt1850
Liabilities53362496
Stockholders' Equity3536701,739
Income Statement ($MM)2016-12-312017-12-312018-12-31
Revenue124198
Cost of Revenue29
Gross Profit170
R&D98269679
SG&A2063195
Tax02-16
Net Income-119-93-674
Cash Flow ($MM)2016-12-312017-12-312018-12-31
Cash Operating-9013-548
Cash Investing-222-356-638
Cash Financing3814901,691